Enterin Inc

Enterin Inc. is a biotechnology company based in Philadelphia, Pennsylvania. The company employs 17 people and generates over $10,000 in annual revenue. Enterin Inc. is focused on developing pharmaceutical therapies that target the gut-brain axis. Their lead compound, ENT-01 (also known as kenterin), is designed to repair dysfunction in the enteric nervous system (ENS) of the gut and improve neural signaling between the gut and the brain. This compound has shown promise in preclinical models of Parkinson's disease, particularly in addressing constipation, a common symptom of the condition. The company's research centers on the link between infections, ENS dysfunction, and the development and progression of neurodegenerative diseases. They aim to become a global leader in therapies that repair the gut-brain axis, ultimately improving the quality of life for patients with Parkinson's Disease and other neurodegenerative conditions. Visit Enterin Inc. online at enterininc.com.